Conestoga Capital Advisors LLC Decreases Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Key Points

Error: One or more errors occurred.

Conestoga Capital Advisors LLC decreased its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 2.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,603,528 shares of the medical instruments supplier's stock after selling 37,745 shares during the period. LeMaitre Vascular comprises approximately 2.0% of Conestoga Capital Advisors LLC's investment portfolio, making the stock its 23rd largest holding. Conestoga Capital Advisors LLC owned approximately 7.10% of LeMaitre Vascular worth $133,173,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LMAT. Consolidated Planning Corp purchased a new position in shares of LeMaitre Vascular during the 1st quarter valued at approximately $947,000. Principal Financial Group Inc. lifted its position in shares of LeMaitre Vascular by 3.0% during the 1st quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock valued at $9,385,000 after buying an additional 3,248 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in shares of LeMaitre Vascular by 9.9% during the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier's stock valued at $23,921,000 after buying an additional 25,680 shares in the last quarter. Linden Thomas Advisory Services LLC lifted its position in shares of LeMaitre Vascular by 3.2% during the 1st quarter. Linden Thomas Advisory Services LLC now owns 35,591 shares of the medical instruments supplier's stock valued at $2,986,000 after buying an additional 1,109 shares in the last quarter. Finally, Alps Advisors Inc. acquired a new position in LeMaitre Vascular in the 1st quarter valued at $354,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Down 0.3%

Shares of NASDAQ:LMAT opened at $86.60 on Monday. The business has a 50-day moving average price of $91.86 and a 200 day moving average price of $86.46. The company has a current ratio of 13.96, a quick ratio of 11.74 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of 42.04, a PEG ratio of 2.23 and a beta of 0.77. LeMaitre Vascular, Inc. has a 12-month low of $71.42 and a 12-month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same period last year, the business posted $0.52 EPS. LeMaitre Vascular's revenue for the quarter was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Investors of record on Thursday, August 21st were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, August 21st. This represents a $0.80 annualized dividend and a yield of 0.9%. LeMaitre Vascular's payout ratio is presently 38.83%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 100,000 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the transaction, the chief executive officer owned 1,727,003 shares of the company's stock, valued at $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director directly owned 2,916 shares in the company, valued at approximately $274,104. The trade was a 46.16% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 120,815 shares of company stock worth $11,280,206. 9.50% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Barrington Research reissued an "outperform" rating and issued a $95.00 price objective on shares of LeMaitre Vascular in a research note on Wednesday, October 15th. Cantor Fitzgerald increased their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Finally, Weiss Ratings reissued a "buy (b-)" rating on shares of LeMaitre Vascular in a research note on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.